Coronavirus / COVID

In a joint announcement, the leaders of the NIH, HHS, and FDA, made comments about this CDC immunization removal.

The FDA committee advisors are recommending the monovalent JN1-lineage-based COVID-19 vaccines preferentially using the LP81 strain.

The company made the decision after the FDA requested more vaccine data for the mRNA-1083 vaccine. Moderna plans to resubmit their Biologics License Application (BLA) for the vaccine later this year.

FDA leadership says they expect more testing for COVID-19 vaccines and that they generate antibody titers in people in order for vaccines to be considered for approval.

The company's Nuvaxovid vaccine is the only recombinant protein-based, non-mRNA COVID-19 immunization available in the US.

Clinical-stage company, Biovie, will study its therapy, bezisterim, for treatment of neurological symptoms associated with the condition. The company expects to have study results in the first half of 2026.

In a large study, Moderna’s investigational vaccine, mRNA-1083, was shown to have noninferiority to other vaccines, and had an acceptable tolerability and safety profile.

Three different studies reveal blood signatures linked to symptoms, immune pathways tied to lung damage, and the efficacy of cognitive training for brain fog.

The company had requested approval for its mRNA-1083 combination vaccine last year. With this setback, the company is now looking at 2026 for approval.

After delays in the review of the COVID-19 vaccine—which missed its April 1 review deadline—the agency has requested new data.

The University of California San Francisco and Gladstone Institutes develop compounds with a 1,000,000-fold reduction in viral titers and 1000 times effective concentration in the brain.

Study of 400,000 pediatric records shows vaccine’s effectiveness in preventing Long COVID during Delta and Omicron waves.

A large study showed these SARS-CoV-2 positive groups were more prone to myocarditis, heart failure, arrhythmias, and chest pain—regardless of prior cardiovascular history or presence of congenital heart disease (CHD).

A new phase 2 trial raises questions about nirmatrelvir-ritonavir’s broader efficacy, as other studies highlight its effectiveness in reducing mortality among immunocompromised COVID-19 patients.

One hospital related the evolution of resistant Acinetobacter baumannii and Pseudomonas aeruginosa in its ICU to the COVID-19 pandemic.

In a new study, Marc Ka-Chun Chong, PhD discusses the antiviral's impact on survival and hospitalization outcomes.

This is the first in a series on the 5 year anniversary of the pandemic. We want to cover a variety of aspects around it, including lessons learned such as testing, vaccine development, and public health policy as well as some ongoing challenges that remain including vaccine hesitancy and an increase in antimicrobial resistant infections.

Shionogi’s investigational antiviral is the first COVID-19 oral therapy that has shown this distinction.

Sarita Shah, MD, MPH, reveals a decline in timely ART initiation from 86.5% in 2019 to 83.9% in 2020, with viral suppression rates dropping from 91.1% to 84.7%, before showing signs of recovery by 2021.

Kellie Hawkins, MD discusses the findings along with the challenges of diagnosing Long COVID in people with HIV, emphasizing the need for improved clinical recognition and education.

Annie Antar, MD, PhD, offers insights around her research on her findings on this subject.

Stacy Lindborg, PhD, highlights the vaccine’s immune response, safety, and global distribution potential.

Katherine L Kahn, MD, discusses the impact of restricted access to Paxlovid on hospitalization and mortality rates in a highly vaccinated population.

Pemivibart (Pemgarda) demonstrated activity against the LP81 variant.

Manjot K Gill, MD, MS, FASRS, FRCS(C), discusses how reduced retinal capillary perfusion may provide insights into Long COVID’s neurological effects and potential treatment approaches.

Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.

The interim results demonstrated a slightly better vaccine effectiveness in individuals who are immunocompetent vs immunocompromised individuals.

The most recent CDC report accounts for 33 million flu illnesses, 430,000 hospitalizations, and 19,000 deaths this flu season, with Influenza A(H1N1) and A(H3N2) as the primary strains.

The company announced its monoclonal antibody, pemivibart (Pemgarda), was denied the emergency use authorization (EUA) for treatment of mild-to-moderate COVID-19 for immunocompromised persons.

Chinese researchers say this newly discovered virus can be transmitted to humans much the way COVID-19 did.